Improved modeling of in vivo kinetics of slowly diffusing radiotracers for tumor imaging

Journal of Nuclear Medicine

Volumn 55, Issue 9, 2014, Pages 1539-1544

  Wilks, Moses Q ^a   Knowles, Scott M ^a   Wu, Anna M ^a   Huang, Sung Cheng ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immuno PET; Minibody; Prostate stem cell antigen (PSCA); Quantitative imaging

Indexed keywords

A11 MINIBODY I 124; PROSTATE STEM CELL ANTIGEN; TRACER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAYESIAN LEARNING; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISSOCIATION CONSTANT; IGNORING DIFFUSION LIMITATION; IMAGE ANALYSIS; IMMUNOREACTIVITY; IN VIVO STUDY; KINETICS; LEARNING ALGORITHM; LEVENBERG MARQUARDT ALGORITHM; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MOUSE; NONHUMAN; PARTIAL DIFFERENTIAL EQUATION; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RADIOLOGICAL PARAMETERS; RECEPTOR DENSITY; SUBVOXEL SPATIAL HETEROGENEITY; XENOGRAFT; ANIMAL; BAYES THEOREM; BIOLOGICAL MODEL; DIFFUSION; IMMUNO-PET; IMMUNOLOGY; MALE; METHODOLOGY; MINIBODY; PROSTATE STEM CELL ANTIGEN (PSCA); PROSTATE TUMOR; QUANTITATIVE IMAGING; SCINTISCANNING;

IMMUNO-PET; MINIBODY; PROSTATE STEM CELL ANTIGEN (PSCA); QUANTITATIVE IMAGING;

ANIMALS; ANTIGENS, NEOPLASM; BAYES THEOREM; DIFFUSION; IODINE RADIOISOTOPES; KINETICS; MALE; MICE; MODELS, BIOLOGICAL; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS;

EID: 84907015954     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.140038     Document Type: Article

References (35)

1. Knowles SM, Wu AM. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol. 2012;30:3884-3892.
2. Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR. Radiopeptide imaging and therapy in Europe. J Nucl Med. 2011;52(suppl 2):42S-55S.
3. Graham MM, Menda Y. Radiopeptide imaging and therapy in the United States. J Nucl Med. 2011;52(suppl 2):56S-63S.
4. Larson SM, Pentlow KS, Volkow ND, et al. PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med. 1992;33:2020-2023.
5. Mumprecht V, Honer M, Vigl B, et al. In vivo Imaging of inflammation-and tumor-induced lymph node lymphangiogenesis by immuno-positron emission tomography. Cancer Res. 2010;70:8842-8851.
6. Pillay V, Gan HK, Scott AM. Antibodies in oncology. N Biotechnol. 2011;28: 518-529.
7. Jones PL, Gallagher BM, Sands H. Autoradiographic analysis of monoclonal antibody distribution in human colon and breast tumor xenografts. Cancer Immunol Immunother. 1986;22:139-143.
8. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F (ab′) 2, and Fab in tumors. Cancer Res. 1989;49:5656-5663.
9. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst. 2006;98:335-344.
10. Langmuir VK, Mendonca HL, Woo DV. Comparisons between two monoclonal antibodies that bind to the same antigen but have differing affinities: uptake kinetics and 125I-antibody therapy efficacy in multicell spheroids. Cancer Res. 1992;52:4728-4734.
11. Thurber GM, Zajic SC, Wittrup KD. Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med. 2007;48:995-999.
12. Weinstein JN, Eger R, Covell D, et al. The pharmacology of monoclonal antibodies. Ann N Y Acad Sci. 1987;507:199-210.
13. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001;61:4750-4755.
14. Saga T, Neumann RD, Heya T, et al. Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci U S A. 1995; 92:8999-9003.
15. Dennis MS, Jin H, Dugger D, et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res. 2007;67:254-261.
16. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6:583-592.
17. Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci. 2008;29:57-61.
18. Huang S-C, Phelps ME. Principles of tracer kinetic modeling in positron emission tomography and autoradiography. In: Phelps M, Mazziotta J, Schelbert H, eds. Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and Heart. New York, NY: Raven Press; 1986:287-346.
19. Graff CP, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids importance of dosage for penetration, and affinity for retention. Cancer Res. 2003;63:1288-1296.
20. Kenanova V, Olafsen T, Crow DM, et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res. 2005;65:622-631.
21. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23:1137-1146.
22. Wu AM. Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med. 2009;50:2-5.
23. Lepin EJ, Leyton JV, Zhou Y, et al. An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging. 2010;37:1529-1538.
24. Knowles SM, Zettlitz KA, Tavaré R, et al. Quantitative immunoPET of prostate cancer xenografts with 89Zr-and 124I-labeled anti-PSCA A11 minibody. J Nucl Med. 2014;55:452-459.
25. Han K-R, Seligson DB, Liu X, et al. Prostate stem cell antigen expression is associated with Gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol. 2004;171:1117-1121.
26. Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A. 1998;95: 1735-1740.
27. Zhigang Z, Wenlv S. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. World J Surg Oncol. 2004;2:13.
28. Leyton JV, Olafsen T, Lepin EJ, et al. Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin Cancer Res. 2008;14:7488-7496.
29. Olafsen T, Gu Z, Sherman MA, et al. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother. 2007;30:396-405.
30. Olafsen T, Kenanova VE, Wu AM. Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protoc. 2006;1:2048-2060.
31. Bao Q, Newport D, Chen M, Stout DB, Chatziioannou AF. Performance evaluation of the Inveon dedicated PET preclinical tomograph based on the NEMA NU-4 standards. J Nucl Med. 2009;50:401-408.
32. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131-137.
33. van Dongen GA, Visser GW, Lub-de Hooge MN, De Vries EG, Perk LR. Immuno- PET: a navigator in monoclonal antibody development and applications. Oncologist. 2007;12:1379-1389.
34. Goodwin DA. Pharmacokinetics and antibodies. J Nucl Med. 1987;28:1358-1362.
35. Deri MA, Zeglis BM, Francesconi LC, Lewis JS. PET imaging with 89Zr: from radiochemistry to the clinic. Nucl Med Biol. 2013;40:3-14.